Skip to main content
Premium Trial:

Request an Annual Quote

ERS Genomics Licenses CRISPR-Cas9 IP to Cosmo Bio

NEW YORK — ERS Genomics said on Thursday that it has nonexclusively licensed its CRISPR-Cas9 intellectual property portfolio to Japanese life science research products company Cosmo Bio.

Financial and other terms of the deal were not disclosed.

Dublin-based ERS was founded to provide access to CRISPR-Cas9 patents held by Emmanuelle Charpentier. The IP is shared with Jennifer Doudna and the University of California, as well as with the University of Vienna.

Recent nonexclusive licensees of ERS's IP include Lepton Pharmaceuticals, Cytosurge, and Sumitomo Pharma.

Earlier this year, the US Patent and Trademark Office found that Broad Institute patents covering CRISPR-Cas9 in eukaryotic cells have priority over the IP ERS manages. At the time, ERS said that the USPTO ruling does not impact any of the licenses it has issued to patents not involved in the interference proceedings, including patents covering a variety of CRISPR compositions such as ones with dual-guide and single-guide strand formats.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.